Primary Peritoneal Serous Adenocarcinoma Active Not Recruiting Phase 2 / 3 Trials for Trametinib (DB08911)

IndicationStatusPhase
DBCOND0030567 (Primary Peritoneal Serous Adenocarcinoma)Active Not Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02101788Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerTreatment